MedTrace Logo

AZD8108 SAD/MAD in Healthy Volunteers

NCT02248818 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 258

Last updated 2017-04-07

Study results available
· View outcomes & findings →

Summary

This is a randomized, double-blind, placebo-controlled study of single and multiple ascending dosage levels of AZD8108 in healthy volunteers. The study includes an up to 28-day screening period, an in-house period during which AZD8108 or placebo will be administered orally as a solution, and a 4- to 10-day follow-up period after discharge.

Conditions

  • Healthy Volunteers

Interventions

DRUG

AZD8108

Drug: AZD8108 Single or Multiple doses administered orally as a solution.

DRUG

Placebo

Placebo to match AZD8108 Single or Multiple doses of matching placebo administered orally as a solution

Sponsors & Collaborators

Principal Investigators

  • Mina Pastagia, MD, MS · Clinilabs, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2015-09-30
Completion
2015-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02248818 on ClinicalTrials.gov